Aastrom to Present at the Needham & Company 11th Annual Healthcare Conference
ANN ARBOR, Mich., March 28, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will present at the Needham & Company 11th Annual Healthcare Conference for institutional investors and venture capital firms. The conference will be held April 3-4, 2012 at the New York Palace Hotel in New York City.
The Aastrom presentation will take place on Tuesday, April 3 from 2:40-3:20 pm (EDT) in the Henry Room. The presentation will be webcast live and will be accessible in archive for a period of 90 days, beginning one hour after the presentation. The URL for live and archived access to the presentation is:http://wsw.com/webcast/needham51/astm/.
Participants should allow approximately five to ten minutes prior to the presentation start time to visit the site and download any streaming media software needed to listen to the webcast.
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced ixmyelocel-T into late-stage clinical development, including a Phase 3 clinical program to study patients with critical limb ischemia and a planned Phase 2b clinical trial in patients with ischemic dilated cardiomyopathy. For more information, please visit Aastrom's website at www.aastrom.com. For more information on the pivotal REVIVE Phase 3 clinical trial, please visit the trial website at www.revivecli.com.
The Aastrom Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3663
CONTACT: Media contact Andrea Coan Berry & Company email@example.com (212) 253-8881 Investor contact Danielle Spangler The Trout Group firstname.lastname@example.org (646) 378-2924